New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

被引：0
|
作者：
Assi, Rita [1 ]
Temraz, Sally [1 ]
Shamseddine, Ali [1 ]
Mukherji, Deborah [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Beirut, Lebanon
来源：
CURRENT DRUG TARGETS | 2016年 / 17卷 / 03期
关键词：
Prostate cancer; androgen receptor; abiraterone; enzalutamide; LIGAND-INDEPENDENT ACTIVATION; CIRCULATING TUMOR-CELLS; ABIRATERONE ACETATE; ENZALUTAMIDE RESISTANCE; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; SPLICE VARIANTS; TYROSINE PHOSPHORYLATION; INCREASED SURVIVAL; AR COREGULATORS;
D O I：
10.2174/1389450116666150907101044
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre- and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.
引用
收藏
页码：290 / 302
页数：13
相关论文
共 50 条
  • [21] Targeting Continued Androgen Receptor Signaling in Prostate Cancer
    Massard, Christophe
    Fizazi, Karim
    CLINICAL CANCER RESEARCH, 2011, 17 (12) : 3876 - 3883
  • [22] Targeting the androgen receptor and overcoming resistance in prostate cancer
    Einstein, David J.
    Arai, Seiji
    Balk, Steven P.
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 175 - 182
  • [23] Targeting the Androgen Receptor in Prostate Cancer - A Resilient Foe
    Nelson, Peter S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11): : 1067 - 1069
  • [24] Strategies for targeting the androgen receptor axis in prostate cancer
    Carver, Brett S.
    DRUG DISCOVERY TODAY, 2014, 19 (09) : 1493 - 1497
  • [25] Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer
    Nikolaos Pyrgidis
    Ioannis Vakalopoulos
    Petros Sountoulides
    Hormones, 2021, 20 : 73 - 84
  • [26] Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer
    Pyrgidis, Nikolaos
    Vakalopoulos, Ioannis
    Sountoulides, Petros
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2021, 20 (01): : 73 - 84
  • [27] Intermittent androgen suppression - A new concept in the treatment of advanced prostate cancer
    Leitenberger, A
    PROGRESS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER, 1997, 5 : 49 - 57
  • [28] Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer
    Marianne D. Sadar
    World Journal of Urology, 2012, 30 : 311 - 318
  • [29] Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer
    Sadar, Marianne D.
    WORLD JOURNAL OF UROLOGY, 2012, 30 (03) : 311 - 318
  • [30] Heterogeneity of androgen receptor content in advanced prostate cancer
    Xu, X
    Fiorentino, M
    MagiGalluzzi, C
    Olesiak, M
    Hahnfeldt, P
    Hlatky, L
    Kaplan, I
    Wishnow, K
    Loda, M
    LABORATORY INVESTIGATION, 1996, 74 (01) : 494 - 494
12345